Lincoln Pharmaceuticals Ltd approves Q2 FY27 results, reporting consolidated revenue of ₹191.35 crore and net profit of ₹20.43 crore.
- Revenue rose 17.1% year on year and 7.9% sequentially.
- EBITDA was ₹33.22 crore, with a 17.4% operating margin; net profit rose 2.2% year on year but fell 43.6% sequentially.
- No exceptional items were reported. The limited-review conclusion was unmodified; the subsidiary’s interim financial information was not independently reviewed.